Wall Street analysts expect Viewray Inc (NASDAQ:VRAY) to report earnings per share (EPS) of ($0.22) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Viewray’s earnings, with estimates ranging from ($0.25) to ($0.19). Viewray posted earnings per share of ($0.11) in the same quarter last year, which would indicate a negative year over year growth rate of 100%. The company is scheduled to report its next earnings results after the market closes on Thursday, May 2nd.

On average, analysts expect that Viewray will report full-year earnings of ($0.82) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.44). For the next financial year, analysts forecast that the firm will report earnings of ($0.65) per share, with EPS estimates ranging from ($0.81) to ($0.24). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Viewray.

Viewray (NASDAQ:VRAY) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. Viewray had a negative return on equity of 58.78% and a negative net margin of 94.36%. The firm had revenue of $20.66 million for the quarter, compared to analysts’ expectations of $20.38 million. During the same period in the prior year, the business posted ($0.38) earnings per share. The business’s revenue was up 3.7% compared to the same quarter last year.

VRAY has been the topic of several research analyst reports. BidaskClub upgraded Viewray from a “hold” rating to a “buy” rating in a report on Tuesday, January 22nd. ValuEngine upgraded Viewray from a “hold” rating to a “buy” rating in a report on Wednesday, January 16th. Guggenheim initiated coverage on Viewray in a report on Tuesday, January 15th. They set a “buy” rating and a $13.00 target price on the stock. B. Riley restated a “buy” rating and set a $12.00 target price (down previously from $13.75) on shares of Viewray in a report on Monday, March 11th. Finally, Zacks Investment Research upgraded Viewray from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a report on Saturday, February 9th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $12.63.

NASDAQ:VRAY traded down $0.24 during trading hours on Tuesday, reaching $7.01. The company had a trading volume of 1,220,282 shares, compared to its average volume of 1,277,845. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.15 and a quick ratio of 4.24. The stock has a market capitalization of $677.66 million, a price-to-earnings ratio of -7.15 and a beta of 1.27. Viewray has a one year low of $4.86 and a one year high of $13.21.

Several hedge funds have recently made changes to their positions in VRAY. FMR LLC boosted its holdings in Viewray by 2.8% in the fourth quarter. FMR LLC now owns 9,561,726 shares of the company’s stock valued at $58,039,000 after acquiring an additional 256,939 shares during the last quarter. BlackRock Inc. boosted its holdings in Viewray by 9.6% in the fourth quarter. BlackRock Inc. now owns 4,932,420 shares of the company’s stock valued at $29,940,000 after acquiring an additional 431,375 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Viewray by 5.6% in the fourth quarter. Perceptive Advisors LLC now owns 3,905,650 shares of the company’s stock valued at $21,715,000 after acquiring an additional 205,650 shares during the last quarter. Vanguard Group Inc boosted its holdings in Viewray by 59.6% in the third quarter. Vanguard Group Inc now owns 3,011,099 shares of the company’s stock valued at $28,183,000 after acquiring an additional 1,124,417 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Viewray by 59.6% in the third quarter. Vanguard Group Inc. now owns 3,011,099 shares of the company’s stock valued at $28,183,000 after acquiring an additional 1,124,417 shares during the last quarter.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Read More: Put Option

Get a free copy of the Zacks research report on Viewray (VRAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.